Home
Learn More
Features & Pricing
Success Stories
Contact Us
Search Archives
PRWeb Direct
Submit Release
October 27, 2008
 
Industry Categories  
News by Country  
News by MSA  
Today's News  
Browse by Day  
PR Trackbacks™  
Featured Videos  
ViewNews™  
eBook Digests  
RSS  
PRWeb, a leader in online news and press release distribution, has been used by more than 40,000 organizations of all sizes to increase the visibility of their news, improve their search engine rankings and drive traffic to their Web site.
 
All Press Releases for February 2, 2001 Subscribe to this News Feed    
 

JOHNS HOPKINS UNIVERSITY AWARDS LASIK EYE DROP TO PARADIGM MEDICAL

Contacts:

Stanley Wunderlich
Consulting For Strategic Growth, Ltd.
Public Relations
Corporate Development Consultants
Tel: 800-625-2236
Fax: 516-625-4523
Email: cfsg@consultant.com

John W. Hemmer
Director of Shareholder Relations
Paradigm Medical Industries, Inc.
Tel: 914-762-2946
Fax: 914-762-4322
Web site: www.paradigm-medical.com

SALT LAKE CITY, UT -- January 30, 2001 - Paradigm Medical Industries, Inc. (NASDAQ:PMED) announced today it has completed an option agreement with Johns Hopkins University giving Paradigm the right to license their new eye drop that promotes faster healing and the reduction of haze post operatively sometimes associated with the popular new laser vision correction surgery, known as Lasik which eliminates the need for glasses. Lasik is currently approved for the correction of near-sightedness and has steadily gained in popularity among the public over the past few years.

According to Paradigms Chairman and CEO, Thomas F. Motter, Lasik has quickly grown into a $3 billion industry. This product will be used prophylactically on all patients undergoing Lasik Surgery because surgeons cannot determine which patients will have a post-operative 'haze problem or slow corneal healing." Mr. Motter also explained, Since it will be in use world-wide on every patient, it has the potential to generate annual revenues of between $500 million and $1 billion. In addition to Lasik, there are millions of other surgical procedures performed each year involving incisions into the cornea for which this product will undoubtedly be used to promote faster healing times thus reducing the dangers of complications from infection and shortening the required exposure time to antibiotics, steroids, and anti-inflammatories."

Dr. David Silver, Ph.D. of the Applied Physics Laboratory at Johns Hopkins and co-inventor of the drop explained that their group learned that there was a need for such a product, scientifically referred to as a 'plasminogen activator, after spending a year as a visiting professor in an honorary chair at Johns Hopkins prestigious Wilmer Eye Institute. I have been aware of Paradigms know-how and talent for the past several years and am confident they will be able to bring the product to market this year," Dr. Silver commented.

We expect this patented product to soon become a necessity for almost all surgical procedures involving the cornea, and serve as a 'flagship product around which an ethical pharmaceutical franchise can be built which is in keeping with Paradigms charter to fill in all squares on the eye care matrix through the introduction of products that are revolutionary and proprietary in each product category," Mr. Motter concluded.

Paradigm Medical Industries, Inc., currently develops, manufactures and markets surgical and diagnostic high-tech breakthrough" proprietary equipment and consumable products in medicine. The companys corporate offices are located at 2355 South 1070 West, Salt Lake City, Utah 84119. Call 801-977-8970 or visit us at our web site at www.paradigm-medical.com.

# # #

This press release contains forward-looking statement that, if not verifiable historical fact, may be viewed as forward-looking statements that could predict future events or outcomes with respect to Paradigm and its business. The predictions embodied in these statements will involve risks and uncertainties and accordingly, Paradigm actual results may differ significantly from the results discussed or implied in such forward-looking statements.


   

OPTIONS
Printer Friendly Version
Email this story to a colleague
CONTACT INFORMATION
Barbara Coen
Consulting For Strategic Growth, Ltd.
Email us Here
ATTACHED FILES

There are no multimedia files attached to this release. If this is your release, you may add images or other multimedia files through your PRWeb News Management Console.

ABOUT PRESS RELEASES
If you have any questions regarding information in these press releases please contact the company listed in the press release. Please do not contact PRWeb. We will be unable to assist you with your inquiry. PRWeb disclaims any content contained in these release. Our complete disclaimer appears here.
 
Disclaimer: If you have any questions regarding information in these press releases please contact the company listed in the press release.
Please do not contact PRWeb®. We will be unable to assist you with your inquiry.
PRWeb® disclaims any content contained in these releases. Our complete disclaimer appears here.

© Copyright 1997-2008, Vocus PRW Holdings, LLC.
Vocus, PRWeb and Publicity Wire are trademarks or registered trademarks of Vocus, Inc. or Vocus PRW Holdings, LLC.

Terms of Service | Privacy Policy | Copyright